"Avorn and Angell are focused on the wrong issue. When it comes to the pricing of new drugs, R&D costs are not the major driver. Nor should they be. The driver should be the value the drug brings to the healthcare system.E se alguém não gosta do sistema devia era combater o sistema de patentes.
when innovation leads to the discovery and development of an important new medicine, then its price, in turn, should be driven by the value that it brings.
Innovation, however, doesn’t guarantee pricing."
Trechos retirados de "Do R&D Costs Matter When It Comes To Drug Pricing?"